Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2002 Nov 12;11(4):319–333. doi: 10.1016/0168-1702(88)90005-6

Mapping of three antigenic sites on the haemagglutinin-neuraminidase protein of Newcastle disease virus

Khatijah Yusoff 1,∗, Mark Nesbit 1, Hazel McCartney 1, Peter T Emmerson 1, Anthony CR Samson 1
PMCID: PMC7133837  PMID: 2464879

Abstract

Nine neutralizing monoclonal antibodies (MAbs), each of which react with the haemagglutinin-neuraminidase (HN) glycoprotein of the Beaudette C strain of Newcastle disease virus (NDV), have been used in competitive binding assays to delineate three non-overlapping antigenic sites A, B and C. Epitopes within these sites have been identified on the basis of cross-reactivity of MAb-resistant mutants against the panel of MAbs, determined by plaque assays and Western blotting. Site A contains three non-overlapping epitopes (A1, A2 and A3). A1 is the only linear epitope; all remaining epitopes are conformational. MAbs which react with epitopes A2 and A3 inhibit neuraminidase activity (NA) when assayed with neuraminlactose. Site B contains three partially overlapping epitopes (B1, B2 and B3) and site C is represented by a single epitope (C1). HN gene sequence analysis of MAb-resistant mutants showed that they each had only single amino acid substitutions which range from amino acid residues 347–460 for site A, 284–325 for site B, and at 481 for the Cl epitope. The apparent molecular mass of the HN glycoprotein of one mutant was increased from 72 to 75 kDa. This correlates well with the creation of an additional potential glycosylation site in this mutant from Asn-Ser-Pro(325) to Asn-Ser-Ser(325).

Keywords: NDV, Haemagglutinin-neuraminidase, Monoclonal antibody, Epitope mapping

References

  1. Air G.M., Els M.C., Brown L.E., Laver W.G., Webster R.G. Location of antigenic sites on the three dimensional structure of the influenza N2 virus neuraminidase. Virology. 1985;145:237–248. doi: 10.1016/0042-6822(85)90157-6. [DOI] [PubMed] [Google Scholar]
  2. Aminoff D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem. J. 1961;81:384–392. doi: 10.1042/bj0810384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Both G.W., Air G.M. Nucleotide sequencing coding for the N-terminal region of the matrix protein of influenza virus. Eur. J. Biochem. 1979;96:363–372. doi: 10.1111/j.1432-1033.1979.tb13048.x. [DOI] [PubMed] [Google Scholar]
  4. Cavanagh D., Davis P.J. Evolution of avian coronavirus IBV: sequence of the matrix glycoprotein gene and intergenic region of several serotypes. J. Gen. Virol. 1988;69:621–629. doi: 10.1099/0022-1317-69-3-621. [DOI] [PubMed] [Google Scholar]
  5. Chambers P., Samson A.C.R. A new structural protein for Newcastle disease virus. J. Gen. Virol. 1980;50:155–166. doi: 10.1099/0022-1317-50-1-155. [DOI] [PubMed] [Google Scholar]
  6. Chambers P., Nesbit M., Yusoff K., Millar M.S., Samson A.C.R., Emmerson P.T. Location of a neutralizing epitope for the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. J. Gen. Virol. 1988;69:2115–2122. doi: 10.1099/0022-1317-69-8-2115. [DOI] [PubMed] [Google Scholar]
  7. Clavell L.A., Bratt M.A. Hemolytic interaction of Newcastle disease virus and chicken erythrocytes. II. Determining factors. Appl. Microbiol. 1972;23:461–470. doi: 10.1128/am.23.3.461-470.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coelingh K.L., Winter C.C., Jorgensen E.D., Murphy B.R. Antigenic and structural properties of the HN glycoprotein of the human parainfluenza type 3 virus: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities. J. Virol. 1987;61:1473–1477. doi: 10.1128/jvi.61.5.1473-1477.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Coelingh K.L., Winter C.C., Murphy B.R., Rice J.M., Kimball P.C., Olmsted R.A., Collins P.L. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J. Virol. 1986;60:90–96. doi: 10.1128/jvi.60.1.90-96.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Engvall E., Perlmann P. Enzyme-linked immunosorbent assay, ELISA III. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J. Immunol. 1972;109:129–135. [PubMed] [Google Scholar]
  11. Gotoh B., Sakaguchi T., Nishikawa K., Inocencio N.M., Hamaguchi M., Toyoda T., Nagai Y. Structural features unique to each of the three antigenic sites on the hemagglutinin-neuraminidase protein of Newcastle disease virus. Virology. 1988;163:174–182. doi: 10.1016/0042-6822(88)90244-9. [DOI] [PubMed] [Google Scholar]
  12. Hsu M.C., Scheid A., Choppin P.W. Reconstitution of membranes with individual paramyxovirus glycoproteins and phospholipid in cholate solution. Virology. 1979;95:476–491. doi: 10.1016/0042-6822(79)90502-6. [DOI] [PubMed] [Google Scholar]
  13. Iorio R.M., Bratt M.A. Monoclonal antibodies to Newcastle disease virus: delineation of four epitopes on the HN glycoprotein. J. Virol. 1983;48:440–450. doi: 10.1128/jvi.48.2.440-450.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Iorio R.M., Bratt M.A. Monoclonal antibodies as functional probes on the HN glycoprotein of Newcastle disease virus: antigenic separation of the hemagglutinating and neuraminidase sites. J. Immunol. 1984;133:2215–2219. [PubMed] [Google Scholar]
  15. Iorio R.M., Lawton K.A., Nicholson P.M., Bratt M.A. Monoclonal antibodies identify a strain-specific epitope on the HN glycoprotein of Newcastle disease virus strain Australia-Victoria. Virus Research. 1984;1:513–525. doi: 10.1016/0168-1702(84)90009-1. [DOI] [PubMed] [Google Scholar]
  16. Iorio R.M., Borgman J.B., Glickman R.L., Bratt M. Genetic variation within a neutralizing domain on the haemagglutinin neuraminidase glycoprotein of Newcastle disease virus. J. Gen. Virol. 1986;67:1391–1403. doi: 10.1099/0022-1317-67-7-1393. [DOI] [PubMed] [Google Scholar]
  17. Jorgensen E.D., Collins P.L., Lomedico P.T. Cloning and neucleotide sequence of Newcastle disease virus hemagglutinin-neuraminidase mRNA: identification of a putative sialic acid binding site. Virology. 1987;156:12–24. doi: 10.1016/0042-6822(87)90431-4. [DOI] [PubMed] [Google Scholar]
  18. Kohama T., Garten W., Klenk H.-D. Changes in conformation and charge paralleling proteolytic activation of Newcastle disease virus glycoproteins. Virology. 1981;111:364–376. doi: 10.1016/0042-6822(81)90340-8. [DOI] [PubMed] [Google Scholar]
  19. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  20. Le Long, Portetelle D., Ghysdael J., Gonze M., Burny A., Meulemans G. Monoclonal antibodies to hemagglutinin-neuraminidase and fusion glycoproteins of Newcastle disease virus: relationship between glycosylation and reactivity. J. Virol. 1986;57:1198–1202. doi: 10.1128/jvi.57.3.1198-1202.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Meulemans G., Gonze M., Carlier M.C., Petit P., Burny A., Le Long. Evaluation of the use of monoclonal antibodies to hemagglutinin and fusion glycoproteins of Newcastle disease virus for virus identification and strain differentiation purposes. Arch. Virol. 1987;92:55–62. doi: 10.1007/BF01310062. [DOI] [PubMed] [Google Scholar]
  22. Millar N.S., Chambers P., Emmerson P.T. Nucleotide sequence analysis of the haemagg-lutinin-neuraminidase gene of Newcastle disease virus. J. Gen. Virol. 1986;67:1917–1927. doi: 10.1099/0022-1317-67-9-1917. [DOI] [PubMed] [Google Scholar]
  23. Millar N.S., Chambers P., Emmerson P.T. Nucleotide sequence of the fusion and haemag-glutinin-neuraminidase glycoprotein genes of Newcastle disease virus, strain Ulster: molecular basis for variations in pathogenicity between strains. J. Gen. Virol. 1988;69:613–620. doi: 10.1099/0022-1317-69-3-613. [DOI] [PubMed] [Google Scholar]
  24. Nishikawa K., Isomura S., Suzuki S., Watanabe E., Hamaguchi M., Yoshida T., Nagai Y. Monoclonal antibodies to the HN glycoprotein of Newcastle disease virus. Biological characterization and use for strain comparisons. Virology. 1983;130:318–330. doi: 10.1016/0042-6822(83)90086-7. [DOI] [PubMed] [Google Scholar]
  25. Nishikawa K., Morishima T., Toyoda T., Miyadai T., Yokochi T., Yoshida T., Nagai Y. Topological and operational delineation of antigenic sites on the HN glycoprotein of Newcastle disease virus and their structural requirements. J. Virol. 1986;60:987–993. doi: 10.1128/jvi.60.3.987-993.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ozawa M., Asano A., Okada Y. Biological activities of glycoproteins of HJV (Sendai virus) studied by reconstitution of hybrid envelope and by concanavalin A-mediated binding: a new function of HANA proteins and structural requirements for F protein in hemolysis. Virology. 1979;99:197–202. doi: 10.1016/0042-6822(79)90055-2. [DOI] [PubMed] [Google Scholar]
  27. O'Sullivan M.J., Marks V. Methods for the preparation of enzyme-antibody conjugates for use in enzyme immunoassay. In: Langone J.J., Vunakis H.V., editors. Vol. 73. Academic Press, Inc; London: 1981. pp. 147–166. (Methods in Enzymology). [DOI] [PubMed] [Google Scholar]
  28. Portner A., Scroggs R.A., Metzger D.W. Distinct functions of antigenic sites of the HN glycoprotein of Sendai virus. Virology. 1987;158:61–68. doi: 10.1016/0042-6822(87)90238-8. [DOI] [PubMed] [Google Scholar]
  29. Russell P.H., Alexander D.J. Antigenic variation of Newcastle disease virus strains detected by monoclonal antibodies. Arch. Virol. 1983;75:243–253. doi: 10.1007/BF01314890. [DOI] [PubMed] [Google Scholar]
  30. Russell P.H., Griffiths P.C., Cannon M.J. A microwell immunoperoxidase test for screening hybridomas and for diagnosing Newcastle disease virus and Sendai virus. J. Immunol. Methods. 1983;61:165–170. doi: 10.1016/0022-1759(83)90159-x. [DOI] [PubMed] [Google Scholar]
  31. Russell P.H., Griffiths P.C., Goswami K.K.A., Alexander D.J., Cannon M.J., Russell W.C. The characterization of monoclonal antibodies to Newcastle disease virus. J. Gen. Virol. 1983;64:2069–2072. doi: 10.1099/0022-1317-64-9-2069. [DOI] [PubMed] [Google Scholar]
  32. Sato H., Hattori S., Ishida N., Imamura Y., Kawakita M. Nucleotide sequence of the hemagglutinin-neuraminidase gene of Newcastle disease virus avirulent strain D26: evidence for a longer coding region with a carboxyl terminal extension as compared to virulent strains. Virus Res. 1987;8:217–232. doi: 10.1016/0168-1702(87)90017-7. [DOI] [PubMed] [Google Scholar]
  33. Samson A.C.R. Anomalous behaviour of Newcastle disease virus haemagglutinin-neuraminidase protein in Western blotting analysis of monoclonal antibody binding sites. J. Gen. Virol. 1986;67:1199–1203. doi: 10.1099/0022-1317-67-6-1199. [DOI] [PubMed] [Google Scholar]
  34. Samson A.C.R., Nesbit M., Lyon A.M., Meulemans G. Identification of haemagglutinin-neuraminidase antibody binding sites by western blot analysis of antibody-resistant mutants and partial digest fragments of Newcastle disease virus. J. Gen. Virol. 1988;69:473–480. doi: 10.1099/0022-1317-69-2-473. [DOI] [PubMed] [Google Scholar]
  35. Schaper U.M., Fuller F.J., Ward M.D.W., Mehrotra Y., Stone H.O., Stripp B.R., De Buysscher E.V. Nucleotide sequence of the envelope protein genes of a highly virulent, neurotropic strain of Newcastle disease virus. Virology. 1988;165:291–295. doi: 10.1016/0042-6822(88)90686-1. [DOI] [PubMed] [Google Scholar]
  36. Scheid A., Choppin P.W. Isolation and purification of envelope proteins of Newcastle disease virus. J. Virol. 1973;11:263–271. doi: 10.1128/jvi.11.2.263-271.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Scheid A., Choppin P.W. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity by proteolytic cleavage of an inactive precursor protein of Sendai virus. Virology. 1974;57:475–490. doi: 10.1016/0042-6822(74)90187-1. [DOI] [PubMed] [Google Scholar]
  38. Sheehan J.P., Iorio R.M., Syddall R.J., Glickman R.L., Bratt M.A. Reducing agent-sensitive dimerization of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus correlates with the presence of cysteine at residue 123. Virology. 1987;161:603–606. doi: 10.1016/0042-6822(87)90158-9. [DOI] [PubMed] [Google Scholar]
  39. Thompson S.D., Portner A. Localization of functional sites on the hemagglutinin-neu-raminidase glycoprotein of Sendai virus by sequence analysis of antigenic and temperature-sensitive mutants. Virology. 1987;160:1–8. doi: 10.1016/0042-6822(87)90037-7. [DOI] [PubMed] [Google Scholar]
  40. Umino Y., Kohama T., Kohase M., Sugaira A., Klenk H.-D., Rott R. Biological functions of monospecific antibodies to envelope glycoproteins of Newcastle disease virus. Arch. Virol. 1984;81:53–65. doi: 10.1007/BF01309296. [DOI] [PubMed] [Google Scholar]
  41. Varghese J.N., Laver W.G., Colman P.M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature (London) 1983;303:35–40. doi: 10.1038/303035a0. [DOI] [PubMed] [Google Scholar]

Articles from Virus Research are provided here courtesy of Elsevier

RESOURCES